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Abstract 
Background: Cryptolepine (CPE) is the major indoloquinoline isolated from the popular West African anti-malarial 
plant, Cryptolepis sanguinolenta. CPE possesses various pharmacological activities with potent anti-malarial activity 
against both chloroquine (CQ)-resistant and -sensitive strains. The search for safe and novel anti-malarial agents and 
combinations to delay resistance development to Plasmodium falciparum directed this work aimed at evaluating the 
anti-malarial interaction and safety of CPE in combination with some artemisinin derivatives.
Methods: The in vitro SYBR Green I, fluorescent-based, drug sensitivity assay using a fixed ratio method was carried 
out on the CQ-sensitive plasmodial strain 3D7 to develop isobolograms from three CPE-based combinations with 
some artemisinin derivatives. CPE and artesunate (ART) combinations were also evaluated using the Rane’s test in ICR 
mice infected with Plasmodium berghei NK-65 strains in a fixed ratio combination (1:1) and fractions of their ED50s in 
order to determine the experimental ED50 (Zexp) of the co-administered compounds. Isobolograms were constructed 
to compare the Zexp to the Zadd.
Results: CPE exhibited promising synergistic interactions in vitro with ART, artemether and dihydroartemisinin. In 
vivo, CPE combination with ART again showed synergy as the Zexp was 1.02 ± 0.02, which was significantly less than 
the Zadd of 8.3 ± 0.31. The haematological, biochemical, organ/body weight ratio and histopathology indices in the 
rats treated with CPE at all doses (25, 50, 100 mg kg−1 po) and in combination with ART (4 mg kg−1) showed no sig-
nificant difference compared to the control group.
Conclusion: The combination of CPE with the artemisinin derivatives were safe in the rodent model and showed a 
synergistic anti-malarial activity in vivo and in vitro. This study supports the basis for the selection of CPE as a prospec-
tive lead compound as the search for new anti-malarial combinations continues.
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Background
Malaria remains one of the world’s leading cause of child-
hood morbidity and mortality and accounts for 10 % of 
childhood deaths in sub-Saharan Africa [1]. In 2015, 214 
million new cases occurred worldwide with the African 
region accounting for most cases (88  %) and mortal-
ity (90 %) from the disease [1]. With the development of 
artemisinin resistance and the delayed parasite clearance 
with the ACT in the Greater Mekong sub-region (GMS) 
[2], the search for safe and selective chemotherapeu-
tic agents with efficacy that will not be compromised 
by Plasmodium remains the focus. The problem of 
resistance of Plasmodium to anti-malarials in the high 
endemic regions has left these regions with high inci-
dence of treatment failure considering the few and 
affordable treatment options available [3].
The contribution of medicinal plants to the develop-
ment of novel anti-malarial combinations cannot be 
underestimated since most of the anti-malarial drugs 
in use are either obtained directly from plants or devel-
oped using lead structures from plants [4]. The limited 
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availability coupled with the high cost of pharmaceuti-
cals in many African countries has resulted in the major-
ity of the populace depending on herbal medicines for 
treatment of several ailments, including malaria [5]. The 
aqueous root extract of Cryptolepis sanguinolenta is a 
well-known anti-malarial agent in West African ethno-
medicine. It has gained popularity among indigenes for 
decades and is now packaged for use in hospitals and 
other herbal centres. Bioactive compounds from medici-
nal plants used traditionally is an important approach 
for identifying novel and potent anti-malarial drug can-
didates. Cryptolepine (Fig. 1) (CPE) is the major indolo-
quinoline alkaloid isolated from C. sanguinolenta. CPE is 
reported to possess several biological activities, including 
antihyperglycaemic [6], antifungal [7], antihypertensive 
[8], antibacterial [9], anti-inflammatory [10], antiplasmo-
dial activities [11–13].
CPE has been studied extensively and has been found 
to be an important lead compound in the search for 
effective and novel anti-malarial drugs. The aqueous root 
extract of C. sanguinolenta is patronized in rural West 
Africa as a herbal extract in the treatment of malaria even 
for patients who are on prescribed artemisinin deriva-
tives. A possible interaction of the herbal extract with 
widely used artemisinin derivatives is not known. The 
present study aimed at determining the possible toxicity 
and anti-malarial interaction (in vitro and in vivo) when 
CPE, the major alkaloid of the plant is combined with 
some artemisinin derivatives. The outcome of the study 
is expected to provide information on the safety, activ-
ity and possible interaction when CPE is combined with 
these standard anti-malarial agents.
Methods
Materials
CPE hydrochloride (purity 98.9  %) was isolated from 
C. sanguinolenta as described by Kuntworbe et al. 
[14]. Briefly, the isolation of the compound proceeded 
through the exhaustive extraction of the root powder of 
C. sanguinolenta by soxhlet with methanol, followed by 
a combination of liquid–liquid extraction and column 
chromatography leading to the isolation of the pure com-
pound in high yield. The isolated CPE was identified by 
the mass spectrometry, thin layer chromatography (TLC), 
High Performance Liquid chromatography (HPLC) and 
the melting point determination. Artemether (ARM) and 
dihydroartemisinin (DHA) (Novartis Pharma AG, Basel, 
Switzerland), artesunate (ART) and ethanol (70 %) were 
obtained from Sigma-Aldrich (St Louis, MO, USA). Gen-
tamicin was obtained from Invitrogen Life Technologies 
Inc. (Carlsbad, CA, USA). RPMI-1640 medium, strepto-
mycin/penicillin, l-glutamine and HEPES were obtained 
from Gibco BRL Life Technologies (Grand Island, NY, 
USA).
Animals
Healthy Sprague-Dawley rats (150-250 g) and mice (ICR) 
infected with Plasmodium berghei NK-65 (chloroquine 
(CQ)-sensitive strain) (25-30 g) were purchased from the 
Noguchi Memorial Institute for Medical Research, Uni-
versity of Ghana, Legon, and kept in the animal house 
of the Department of Pharmacology, Kwame Nkrumah 
University of Science and Technology (KNUST), Kumasi, 
Ghana. The malaria parasites in the mice were kept alive 
by continuous intraperitoneal passage to healthy mice 
every 4 days [15]. These infected mice were used for the 
antiplasmodial study.
All animals were housed under constant environmen-
tal conditions (21 ±  2  °C, 40 ±  5 % humidity, and 12-h 
light-dark cycles) and were allowed free access to food 
and water. The rodents were housed in stainless cages 
(35 × 48 × 18 cm) with soft wood shavings as bedding 
and allowed free access to water and commercial feed 
(Agricare, Tanoso, Kumasi, Ghana). All animals were 
fasted overnight (12  h) before oral dosing but food was 
returned to cages 4  h post oral dose. All animals used 
were naïve and used only once. The use of animals was in 
agreement with the National Institute of Health Guide-
lines for Care and Use of Laboratory Animals (1985) 
and was approved by the Ethical Review Committee of 
the Faculty of Pharmacy and Pharmaceutical Sciences, 
KNUST, Ghana (PHARM/ETHIC/ET173/15).
In vitro malaria parasite cultivation
The asexual intra-erythrocytic stage of Plasmodium fal-
ciparum laboratory strain 3D7 was continuously cul-
tured in vitro based on the approach described by Trager 
and Jensen [16] with slight modifications. The parasites 
were cultured in erythrocytes (sickling negative; O rhe-
sus positive) fortified in complete culture medium (pH 
7.3). The complete culture medium consisted of filter-
sterilized RPMI 1640 solution supplemented with 0.5  % 
AlbuMAX II and hypoxanthine (0.04 %) and buffered Fig. 1 Cryptolepine hydrochloride
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with 0.4  % sodium bicarbonate (NaHCO3) and 0.72  % 
HEPES (N-2-hydroxyethylpiperazine-N-2-ethanesulfonic 
acid). Gentamicin (0.005 mg/mL) was added to the final 
solution.
The parasites were grown in culture flasks incubated 
under a gas phase of 92  % N2, 5  % CO2 and 3  % O2 at 
37  °C. The cultures were maintained daily by changing 
the media and monitoring parasite viability and growth 
by light microscopy. Parasitaemia levels in the cultures 
were kept between 2 and 8 %, with 5 % haematocrit.
In vitro anti‑malarial interaction assay
The in vitro anti-malarial activity of CPE and in combi-
nation with the artemisinin derivatives against P. falcipa-
rum (3D7, CQ sensitive) was investigated using the SYBR 
Green I-based fluorescence assay [17]. d-Sorbitol treat-
ment (5  %) was used to generate parasite cultures with 
high synchronous ring stage for each assay.
Stock solutions of drugs were prepared in 70  % etha-
nol. CPE, ART, ARM, and DHA stocks were prepared at 
1  mM. The concentration ranges of CPE were between 
32.5 and 2080 nM, those for ART were between 0.5 and 
32 nM, and those for ARM and DHA were between 0.625 
and 48  nM. Previously described fixed ratio interaction 
assay was employed [18] in the investigation of the com-
bined effects of CPE with these artemisinin derivatives. 
A volume of 10 µL of four fixed drug ratios (4:1, 3:2, 2:3, 
1:4) of CPE (Drug A) with an artemisinin drug (Drug B) 
were prepared in each of the assay medium. This was fol-
lowed by twofold serial dilutions of each well and ensur-
ing that the IC50 of each drug alone (5:0 and 0:5) falls 
approximately at the mid-point of the serial dilution. 
Each culture well was further seeded with 90 µL of para-
site culture to obtain seven desired final concentrations 
for each combination assay. The final haematocrit of cul-
tures were adjusted to 2 % by dilution with complete par-
asite medium (CPM) and parasitaemia was stepped down 
to 1  % with washed uninfected red blood cells (RBCs). 
The plates were arranged in a clean modular incubation 
chamber (Billups-Rothenberg Inc, USA) and flushed 
with mixed gas (gas contains 92 % N2, 5 % CO2, 3 % O2) 
for 5 min. The chamber with the assay plates was placed 
in an incubator for 48 h and set at 37 °C. After the 48-h 
incubation, the plates were wrapped in aluminium foil 
and stored at −30 °C overnight.
The plates were thawed and thoroughly mixed with 
100  μL malaria SYBR Green 1 fluorescent (MSF) lysis 
buffer containing SYBR Green. The plates were incubated 
at room temperature in the dark for an hour and fluores-
cence data were acquired using fluorescence multi-well 
plate reader (Tecan Infinite M200 Pro) with emission 
and excitation wavelength at 535 and 485  nm, respec-
tively. The experiment was done in triplicate. The plates 
were examined for the RFU per well. The fluorescence of 
the non-parasitized RBCs and the background fluores-
cence of the empty well were each subtracted from the 
fluorescence readings. The resultant fluorescence were 
converted to percentages and plotted against the log of 
the drug concentration. The data obtained was analysed 
using GraphPad Prism (GraphPad 6 Software, San Diego, 
CA, USA) by non-linear regression (sigmoidal dose-
response/variable slope equation) to yield the IC50 (50 % 
inhibitory concentration) which served as a measure of 
the anti-malarial activity.
In vivo anti‑malarial interaction assay
The ED50 of CPE was estimated using the curative (Rane) 
test as described by [19]. In this test, schizonticidal activ-
ity of CPE was determined in established infection. On 
day 0, Giemsa-stained thin blood smear of the donor 
mice were prepared to determine the RBC count and 
percentage parasitaemia by using an improved Neu-
baur Counting Chamber. Blood from donor mice was 
obtained by cardiac puncture. Physiological saline was 
used in diluting the collected blood. Each mouse was 
intraperitoneally injected with 0.2 ml of 1 × 106 P. berghei 
NK-65-infected erythrocytes on the first day (day 0).
After 72 h, and following confirmation of parasitaemia, 
the mice were divided into five groups of five mice per 
group. These groups were treated with CPE at doses of 
3, 10, 30, and 100  mg  kg−1. The positive control group 
was treated with ART (1, 3, 10 and 30  mg  kg−1) and 
10 ml kg−1 of physiological saline was given to the nega-
tive control group. The drug treatment lasted 5  days at 
a single daily dosing. Blood smears were collected daily 
before each drug administration and monitored for the 
parasitaemia level under the microscope.
To obtain the combination potency of the co-admin-
istered CPE and ART, the two agents will be assayed for 
anti-malarial activity as describe earlier at doses of their 
respective ED50’s (equi-effective doses) and in fixed ratio 
combinations (1:1) of fractions of their respective ED50 
values of 1/2, 1/4, 1/8, 1/16 [20, 21]. The ED50 for the com-
bination (Zexp) will also be determined as described ear-
lier. To determine the type of interaction exhibited by the 
co-administration, an isobologram consisting of CPE on 
the abscissa and ART on the ordinate will be constructed. 
The Zexp will be plotted and compared to the Zadd sta-
tistically using‘t’ test. Synergistic anti-malarial effect will 
be achieved when the Zexp is higher (ED50 significantly 
lower) than the Zadd. If the ED50’s are not statistically dif-
ferent, the effect of the combination is additive. Antago-
nistic anti-malarial effect will be observed when the Zexp 
is significantly higher than the Zadd.
On day 9 post malaria infection, all the mice from 
each co-administered group were sacrificed and blood 
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collected by cardiac puncture for haematological analy-
sis. The stomach, liver and kidneys were also harvested 
for histopathological analysis.
Safety evaluation of CPE and ART in healthy rats
Healthy male Sprague-Dawley rats (150–250  g) were 
divided into eight groups of five animals in each group. 
The groups received 25, 50 and 100 mg kg−1 body weight 
of CPE orally, daily for a period of 3 days. Another set of 
groups received a concurrent administration of CPE 25, 
50 and 100 mg kg−1 body weight with ART (4 mg kg−1) 
orally for 3  days. A group of five animals each also 
received 4 mg kg−1 of ART orally, daily for a 3-day period. 
The control group received equal volume of physiologi-
cal saline solution for the period of the experiment. Each 
group was then closely observed for signs of toxicity.
On the third day, the rats were sacrificed by cervical 
dislocation, the jugular vein cut and blood allowed to 
flow freely into tubes with and without ethylenediami-
netetraacetic acid (EDTA) as coagulant. Haematologi-
cal and biochemical parameters were determined by an 
automatic analyser (Sysmex XT-2000 L CELL-DYN 1700, 
Abbot Diagnostics Division, Abbot Laboratories, Abbot 
Park, IL, USA) and automated analyser ATAC 8000 Ran-
dom Access Chemistry System (Elan Diagnostics, Smith-
field, RI, USA), respectively. Selected organs including 
the spleen, liver, kidneys, and stomach were excised, 
trimmed of fat and connective tissue, blotted dry and 
weighed on a balance. The relative weights of the organs 
were calculated and expressed as per cent of body weight.
Toxicological assessment of CPE and ART co‑administration 
in the Rane’s test
Sections of the tissue from the stomach, kidney, spleen, 
and liver of both healthy rats and P. berghei-infected mice 
were used for histopathological examination. Samples col-
lected were washed separately in physiological saline and 
fixed in formalin (buffered with 10 % NaH2PO4) for 24 h 
and used for the histology study. Previously described 
method reported by [22] was used in the processing of the 
tissues. Tissue sections of each target organ were fixed in 
Bouin’s solution for 12  h and embedded in paraffin. For 
histopathological examination, tissues sections (5  µm) 
were rehydrated, stained with haematoxylin and eosin (H 
and E) and observed under light microscope.
Data analysis
In vitro anti‑malarial interaction assay
Growth inhibition due to CPE and the other anti-
malarial agents defined as the difference between the 
percentage parasitaemia of each treatment group and 
the corresponding control was calculated. The FIC50s 
for each fixed dose ratio were calculated from the 
IC50 values obtained from the dose-response curves. 
ΣFIC50s of CPE with the artemisinin derivatives were 
represented as isobolograms calculated using the 
equation:
The FIC50 of CPE was plotted against each of the anti-
malarial agent to obtain isobolograms representing each 
of the four drug ratios. Convex curves denote antagonism; 
straight lines denote additivity and concave curves denotes 
synergy [18]. The nature of the interaction was explained 
using the following ΣFIC50 values: ΣFIC50 <0.8 indicates 
synergism, ΣFIC50 0.8–1.4 indicates additive, ΣFIC50 ≥1.4 
indicates antagonism [23, 24]. The overall nature of the 
anti-malarial interaction was based on the mean ΣFIC50s.
In vivo anti‑malarial interaction assay
The antiplasmodial activity was determined using the 
equation:
The potency of CPE and ART were estimated from 
their log-dose response curves. An isobologram consist-
ing of an additivity line that connects ED50, Drug A on 
the vertical axis to ED50, Drug B on the horizontal axis 
was plotted. The estimated potencies (ED50s) of CPE and 
ART in both tests were also used to compute the theo-
retical potency (Zadd) as follows:
where f is the fraction of the each component in the 
mixture.
For the combination assay, mid points (ED50’s) will be 
determined using nonlinear regression (three-parame-
ter logistic) equation: The fitted midpoints of the curves 
(Zexp and Zadd) will be compared statistically using t 
test.
Data for toxicity studies were presented as 
Mean  ±  SEM. The GraphPad Prism one-way ANOVA 
(GraphPad Software Ver. 6, San Diego, CA, USA) was 
used to establish any significance differences among 
means of groups. The Newman–Keuls multiple com-
parison test was used to establish significant difference 
between pairs of groups.
FIC50 =
(
IC50 of cryptolepine in combination




IC50 of Drug B in combination




Parasitaemia of negative control− Parasitaemia of test
Parasitaemia of negative Control
× 100
Zadd = f (ED50) of artesunate + (1− f )ED50 of
cryptolepine
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Results
In vitro anti‑malarial interaction assay
The stage-specific IC50 of CPE and the artemisinin 
derivatives on P. falciparum blood-stage cultures is 
shown in Table  1. In the interaction assays, the combi-
nations of CPE with ART, ARM, and DHA were syner-
gistic (Table  2). CPE combination with the artemisinin 
derivatives showed FIC50 of less than 0.8 suggesting 
synergy. The degree of synergism was stronger in ARM 
(ΣFIC50 = 0.362), followed by DHA (ΣFIC50 = 0.403) and 
finally ART (ΣFIC50 = 0.693) (Fig. 2). The isobolograms 
for the various interactions are shown in Fig. 3.  
The IC50 levels for the drugs alone were 6.76 ±  1.63, 
2.59 ± 0.59, 6.02 ± 0.17 and 603.82 ± 75.57 nM, respec-
tively, for ART, ARM, DHA, and CPE.
In vivo assays
CPE produced a significant dose-dependent reduc-
tion in parasitaemia levels with similar reduction as in 
the ART-treated groups (positive control). The poten-
cies of CPE and ART were 10.65  ±  0.60  mg  kg−1 and 
6.0 ± 0.05 mg kg−1 in the anti-malarial test (Table 3).
Combination anti‑malarial assay of CPE and ART
The combination of CPE (ED50=40  mg  kg−1) and ART 
(ED50=6  mg  kg−1) produced a significant reduction 
in parasitaemia from days 1 and 6. The combination of 
Table 1 IC50 values of  cryptolepine and  the artemisinin 
derivatives against 3D7 strain of Plasmodium falciparum
Values are Mean ± SEM from less than seven independent experiments
Drug Mean IC50 ± SEM (nM)
Cryptolepine HCl 603.82 ± 75.57
Artesunate 6.76 ± 1.63
Artemether 2.59 ± 0.59
Dihydroartemisinin 6.02 ± 0.17
Fig. 2 Dose-response curves from the fixed-dose combinations of cryptolepine and artesunate. Ring-stage parasites were treated with fixed-dose 
combinations of cryptolepine and artesunate at 48 h after which analysis was done using the SYBR Green I fluorescent method. Each value repre-
sents the IC50 calculated from at least three independent in vitro experiments
Table 2 Fixed-ratio interaction of drugs against Plasmodium falciparum 3D7 strains
The ratios 4:1, 3:2, 2:3 and 1:4 refer to fixed dose ratios for cryptolepine to the arteminisins. Values are expressed as the means from at least three in vitro experiments
Drug combination ΣFIC50 Mean ΣFIC50 Interaction
4:1 3:2 2:3 1:4
Cryptolepine + artemether 0.4891 0.4727 0.3094 0.1765 0.362 Synergism
Cryptolepine + artesunate 0.8658 0.9469 0.433 0.530 0.693 Synergism
Cryptolepine + dihydroartemisinin 1.214 0.0906 0.1263 0.181 0.403 Synergism
Page 6 of 12Forkuo et al. Malar J  (2016) 15:89 
CPE and ART at all dose levels produced high percent-
age suppression in the first 3 days compared to CPE only. 
The lowest dose ratio combination (1/8:1/8) showed 
high parasite levels on days 5 and 6 compared to the 
negative control group (Table  4). The theoretical ED50s 
of CPE and ART combination was 8.3 ±  0.25  mg  kg−1. 
The experimental ED50 (Zexp) of the mixture was 
1.02 ± 0.02 mg kg−1. The Zexp (open circle) lay signifi-
cantly below the line of additivity as well as the Zadd 
(closed circles) on the isobologram indicating synergism 
(Fig. 4). The degree of interaction calculated as the inter-
action index was 0.12 (Table 5).
Toxicological assessment of CPE and ART in healthy rats
Haematological values of treated rats were not signifi-
cantly different from those of the control group for all 
parameters measured at doses of (25–100 mg kg−1) CPE 
except for the mean corpuscular volume (MCV) and 
the mean corpuscular haemoglobin (HGB) concentra-
tion (MCHC), which were significantly decreased in the 
Fig. 3 Effects of combinations of cryptolepine with the artemisinin derivatives on Plasmodium falciparum growth in vitro (3D7 strain). Isobolograms 
show the effect of combinations of both cryptolepine with artemether (a), artesunate (b) and dihydroartemisinin (c). The interaction between 
cryptolepine and artesunate, artemether, or dihydroartemisinin against ring-stage parasites were determined using the SYBR Green I fluorescent-
based drug sensitivity assay using the fixed ratio method. Each combination was set up in triplicate for 48 h. The FIC50 concentrations were used in 
the plotting of the isobolograms
Table 3 ED50 of  cryptolepine and  artesunate in  the anti-
malarial test




Cryptolepine 10.65 ± 0.6
Artesunate 6.0 ± 0.05
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group treated concomitantly with CPE (100 mg kg−1) and 
ART (4 mg kg−1) (Table 6).
The oral administration of CPE only as well as with 
ART did not cause any significant changes in serum pro-
teins, bilirubin, liver enzymes, creatinine, urea, and uric 
acid.
Haematological analysis of Plasmodium berghei‑infected 
mice treated with various concentrations of CPE and ART
Figure  5 shows the haematological parameters after 
5  days of treatment. A significant increase in platelet 
(PLT) count was observed in all groups treated with CPE 
compared to the vector control. Lymphocyte (LYMP) lev-
els were generally lowered in all groups compared to the 
vector control.
Histopathology
The livers, kidneys, spleens, and stomachs from the dis-
tilled water-treated (control) group had normal appear-
ance and histology. Generally, no observable changes 
in the architecture of these organs of treated animals 
compared to the control (Figs. 6, 7). The histology of the 
liver and kidney were consistent with the normal alanine 
transaminase, alkaline phosphate, bilirubin, creatinine, 
and urea levels observed in the serum.
Table 4 Percentage suppression of P. berghei infected mice given combination treatment
Values are expressed as Mean ± SEM from five independent experiments
Drugs Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
Artesunate 6 mg/kg 40.74 ± 10.4 89.87 ± 2.2 97.92 ± 1.3 90.20 ± 2.1 87.40 ± 6.9 90.44 ± 2.5
Cryptolepine 40 mg/kg 53.70 ± 13.1 57.81 ± 4.0 65.3 ± 7.5 77.48 ± 15.2 82.16 ± 5.4 83.19 ± 6.4
ED50 (1:1) 73.15 ± 9.8 95.78 ± 9.8 93.06 ± 1.39 68.03 ± 12.6 78.35 ± 9.0 88.53 ± 4.4
ED50/2 (1/2:1/2) 80.56 ± 3.7 79.75 ± 5.24 88.89 ± 2.8 85.03 ± 2.7 90.81 ± 3.47 92.35 ± 2.2
ED50/4 (1/4:1/4) 87.96 ± 3.1 96.84 ± 1.1 76.39 ± 6.1 85.03 ± 6.8 82.94 ± 3.5 84.70 ± 2.2
ED50/8 (1/8:1/8) 86.11 ± 1.46 86.50 ± 2.5 77.08 ± 6.9 0.51 ± 14.65 −23.0 ± 12.4 −8.03 ± 10.3
ED50 cryptolepine (mg/kg)









Fig. 4 Isobologram for the combination of cryptolepine and artesu-
nate in the Rane’s anti-malarial test. The open circles and filled circles 
represent the experimental and theoretical ED50s ± SEM, respectively
Table 5 Experimental (Zexp) and  theoretical (Zadd) 
ED50 ± SEM values of cryptolepine and artesunate in anti-
malarial test
Values are expressed as Mean ± SEM
*** P < 0.001 compared to their respective Zadds
Zexp (mg kg−1) Zadd (mg kg−1) Interaction index
1.02 ± 0.02*** 8.3 ± 0.25 0.12
Table 6 Effects of the concomitant administration of cryptolepine and artesunate 4 mg kg−1 on the haematological indi-
ces of Sprague-Dawley rats treated for 3 days
Cryptolepine was combined with a fixed dose of artesunate (4 mg kg−1 ). Values are expressed as mean ± SEM (n=5), compared to the controls (ANOVA) followed by 
Student‘s Newman–Keuls multiple comparison test
Asterisk indicates significance (P < 0.05)
Parameters Control Cryptolepine
25 mg kg−1 50 mg kg−1 100 mg kg−1
WBC (×103/µL) 9.83 ± 1.63 8.37 ± 1.54 13.03 ± 2.28 12.73 ± 1.04
RBC (×106/µL) 6.41 ± 0.45 6.86 ± 0.26 6.58 ± 0.24 6.47 ± 0.29
HGB (g/dL) 11.63 ± 0.93 12.07 ± 0.20 11.77 ± 0.23 11.93 ± 0.12
HCT (%) 39.27 ± 1.68 38.4 ± 1.07 37.3 ± 0.90 35.3 ± 1.15
MCV (fL) 61.7 ± 2.19 56.03 ± 0.63 56.77 ± 0.72 54.63 ± 0.68*
MCH (pg) 18.13 ± 0.69 17.67 ± 0.44 17.9 ± 0.37 18.53 ± 0.69
MCHC (g/dL) 29.43 ± 1.15 31.47 ± 0.44 31.57 ± 0.45 33.87 ± 0.83*
PLT (×103/µL) 516.33 ± 76.50 821.33 ± 9.02 725.67 ± 67.65 843.67 ± 44.67
LYMP (%) 72 ± 4.18 75.73 ± 2.80 77.38 ± 1.73 83.43 ± 2.84
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Discussion
The discovery of artemisinin and its derivatives from the 
leafy portions of Artemisia annua has been the major 
advance in the chemotherapy of malaria [25]. ACT is 
now the mainstay in the treatment of uncomplicated 
malaria due to the high efficacy and low probability of 
drug-resistance development [26].
The present study focuses on the combination of the 
plant-derived anti-malarial compound, CPE, with the 
widely used artemisinin derivatives, with the aim of 
developing novel artemisinin combinations to forestall 
the progression of resistance to these agents. Several 
reports on the antiplasmodial activities of extracts of C. 
sanguinolenta and its major alkaloid, CPE, have been 
extensively studied in  vivo and in  vitro [11, 12]. In this 
study, the interactions observed when this indoloquino-
line is combined with some artemisinin derivatives both 
in vitro and in vivo were demonstrated. The susceptibili-
ties of CPE and the standard drugs in  vitro were close 
to those reported in literature [27, 28]. The in vitro anti-
malarial interactions of the different combinations are 
shown in the isobologram analysis in Figs. 3 and 4. CPE 
in combination with ART, ARM and DHA had the ΣFIC 
always below the line of additivity. The values obtained 
with these three artemisinins indicate a synergistic inter-
action of the artemisinins with CPE. The mechanism of 
action of the indoloquinolones has been shown to be 
similar to that of CQ in inhibiting the conversion of poi-
sonous haem to haemozoin (β-haematin) in the parasite 
food vacuole [29].
In the in vivo assay, all the combination treatment pro-
duced a more significant reduction in parasitaemia com-
pared to the use of only CPE or ART on the first day of 
treatment. This translated into a synergistic effect when 
the two agents were used together. The rapid onset of 
anti-malarial activity continued through to the first 
3  days of the combination treatment at all dose ratios. 
This indicates a possible rapid onset of antiplasmodial 
activity when CPE is used in combination with ART 
compared to each of the drugs used alone. With the cur-
rent 3 day anti-malarial treatment, a combination of CPE 
with ART may offer better choice for rapid clearance of 
parasites in the blood compared to any of the two agents 
used alone. Again, the long duration of action of this 
combination will ensure efficient parasite clearance. The 
mechanisms involved in the enhanced activity observed 
with CPE-artemisinin combinations have not yet been 
elucidated. However, concerning the synergistic effect 
observed with the artemisinins and amodiaquine, further 
studies should be performed with CPE alone and in com-
bination on several P. falciparum strains and/or rodent 
malaria models to highlight the biochemical mechanisms 
behind its antiplasmodial interactions. On this basis, it is 
strongly believed that the combination of CPE with the 
artemisinin derivatives is a legitimate choice for an alter-
native anti-malarial combination development.
The haematological parameters showed no signifi-
cant difference in the total white blood cell count in all 
treated groups compared to the vector control, except 
the group treated with the combination of the ED50 of 
CPE and ART (1:1 ratio). The LYMP levels were signifi-
cantly decreased in all combination treatments. Gener-
ally, malaria infections are usually associated with low 
levels of LYMPs indicative of a compromised immune 
response [30]. In a clinical trial using tea bags contain-
ing C. sanguinolenta, a progressive increase in PLT count 
after treatment was observed in the human subjects used. 
Fig. 5 Effect of cryptolepine and artesunate on the haematological 
indices (a Platelets b Lymphocytes) of Plasmodium berghei-infected 
ICR mice treated for 6 days. Values are expressed as Mean ± SEM 
(n=5), Asterisk indicates significance (P < 0.05), double Asterisk indi-
cates significance (P < 0.01) and triple Asterisk indicates significance 
(P < 0.001) compared to controls (ANOVA) followed by Student’s 
Newman–Keuls multiple comparison test
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The high PLT count observed was concluded as an indi-
cation of the effectiveness of the tea bag against falcipa-
rum malaria [31]. In the current study, the PLT count 
in all CPE-treated groups was significantly increased (P 
<0.001) compared to the vector control. This may be an 
inherent attempt to boost the acute thrombocytopae-
nia and immune suppression usually accompanied with 
malaria [32]. PLTs assist and modulate inflammatory 
reactions and immune responses. The lowest dose ratio 
of CPE with ART did not show any significant change in 
the PLT level compared to the vector control.
The administration of C. sanguinolenta to rats has been 
shown to cause hyperplasia and hypertrophy of gastric 
parietal cells [33]. In this study, the histology of the stom-
ach of mice treated with CPE and the various combinations 
were examined. No observable defects were observed in 
the architecture of the stomach of the mice. The liver archi-
tecture showed no deformity in the drug-treated group 
compared to the control. This, coupled with no reported 
deaths in the 9-day treatment shows the safety of the com-
bination of CPE with ART in the acute treatment in mice.
The safety evaluation of CPE when used with the ART 
was further determined in healthy Sprague-Dawley rats. 
The analysis of the cellular component of blood is per-
tinent to risk assessment as the haematological system 
provides predictive indices for toxicity in mammals [34]. 
CPE at all dose levels showed no significant detrimental 
effect in the haematological parameters evaluated com-
pared to the control group for the 3-day period. The con-
current use of CPE did not cause any significant change 
in the haemoglobin (Hb) concentration, therefore the 
reduced MCV reflected in a rise in MCHC, a measure of 
the average concentration of haemoglobin in a RBC. The 
RBCs in this case appeared microcytic however; the hae-
moglobin levels in cells were not affected.
The levels of cellular enzymes in the serum and other 
body fluids play an important role in the diagnosis of 
tissue and organ injury [35]. Aspartate and alanine 
transaminases are useful marker enzymes in assess-
ing liver damage [36] and their detection in the serum 
is indicative of possible liver dysfunction [37]. However, 
they are not always good indications of how well the liver 
Fig. 6 Photomicrograph (×100) showing histopathological slides of the spleen of cryptolepine (CPE) and/artesunate (ART, 6 mg kg−1) treated rats. 
a Control b Artesunate 6 mg kg−1 c CPE 100 mg kg−1d CPE 100 mg kg−1 + ART 6 mg kg−1, all treated for 3 days
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is functioning as elevation of these enzymes are often 
unexpectedly encountered on routine blood screen-
ing test in otherwise healthy individuals [38]. CPE with 
or without ART showed no significant difference in the 
biochemical parameters compared to the control group. 
Microscopic observations revealed a normal hepatocyte 
Fig. 7 Photomicrograph (×100) showing histopathological slides of the livers of cryptolepine (CPE) and/or artesunate (ART, 6 mg kg−1) treated 
Plasmodium berghei-infected mice. a Control, b ED50 of ART (6 mg kg
−1), c ED50 of CPE (10.7 mg kg
−1) d ED50 (CPE + ART) e ½ ED50 (CPE + ART) f ¼ 
ED50 (CPE + ART)
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architecture with a well-defined central vein. No necro-
sis, steatosis, chronic inflammatory infiltration, or degen-
erative changes were observed in any of the drug-treated 
animals. Gross morphological inspection of other organs 
(kidney, spleen and stomach) also revealed no appar-
ent damage. The results were consistent with the liver 
and kidney function test, which showed values not sig-
nificantly different from the controls used. In the P. 
berghei-infected mice, histopathology of the liver, spleen, 
stomach, and kidney in all treatment groups were not dif-
ferent from the control groups. Despite these reports of 
safety in the acute toxicity studies in rodents, CPE has 
been reported to be a DNA intercalator and also possess 
genotoxic properties in mammalian cells [39]. Though 
this study did not focus on possible chronic toxicity, anti-
malarial combination therapies are mostly taken over a 
3-day period. Potential chronic toxicity from such combi-
nations can therefore be precluded. Generally, therefore 
combination therapy of CPE–ART demonstrated in the 
present study appears safe.
Conclusion
The combination of CPE with the artemisinins showed 
a synergistic effect both in  vivo and in  vitro against P. 
berghei NK-65 and P. falciparum 3D7, respectively. The 
combination of CPE with ART did not cause acute toxic-
ity as no significant changes in histopathology, biochemi-
cal and the haematological parameters were observed in 
healthy Sprague-Dawley rats.
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